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Abstract
Epstein-Barr virus (EBV) is a human herpesvirus, which is causally associated with the development of several B lymphocytic
malignancies that include Burkitt’s lymphomas, Hodgkin’s disease, AIDS and posttransplant associated lymphomas. The
transforming activity of EBV is orchestrated by several latent viral proteins that mimic and modulate cellular growth
promoting and antiapoptotic signaling pathways, which involve among others the activity of protein kinases. In an effort to
identify small molecule inhibitors of the growth of EBV-transformed B lymphocytes a library of 254 kinase inhibitors was
screened. This effort identified two tyrosine kinase inhibitors and two MEK inhibitors that compromised preferentially the
viability of EBV-infected human B lymphocytes. Our findings highlight the possible dependence of EBV-infected B
lymphocytes on specific kinase-regulated pathways underlining the potential for the development of small molecule-based
therapeutics that could target selectively EBV-associated human B lymphocyte malignancies.
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Introduction
Epstein-Barr virus (EBV) is a human c-herpesvirus that infects B
lymphocytes as well as epithelial cells. Latent EBV infection is
associated with several malignancies of B lymphocytes that include
Burkitt’s lymphomas, Hodgkin’s lymphomas, AIDS-associated
lymphomas, and post-transplantation lymphoproliferative disor-
ders (PTLDs). In vitro, EBV can transform resting B cells into long-
term proliferating lymphoblastoid cell lines (LCLs). LCLs display
type III latency, in which a limited set of viral genes is expressed.
This set includes six EBV nuclear antigens (EBNA 1, 2, 3A, 3B,
3C and-LP), three membrane proteins (LMP1, LMP2A and
LMP2B), two short non-polyadenylated RNAs (EBER1 and
EBER2) and transcripts from the BamHI A region of EBV
(BARTs) (reviewed in [1]). The process of B lymphocyte
transformation by EBV relies on the usurpation of cellular growth
promoting and antiapoptotic signaling pathways by viral proteins.
For example, LMP2A mimics and modulates the signaling
pathway of B-cell antigen receptor (BCR) whereas the LMP1
oncoprotein mimics a constitutively active CD40 receptor [2,3].
These signaling pathways involve a number of protein kinases,
which are functionally modulated by the activity of latent EBV
antigens.
BCR is composed of a tetrameric complex of immunoglobulin
(Ig) polypeptides (two heavy and two light chains) in association
with Iga (CD79A) and Igb (CD79B) molecules. Iga and Igb
contain a cytoplasmic immunoreceptor tyrosine-based activation
motif (ITAM) [4]. ITAMs transmit signals that lead to the
activation of several protein tyrosine kinases (PTKs), including
those of Src family (such as Fyn, Lyn, Lck and cSrc), spleen
tyrosine kinase (Syk) and Bruton’s tyrosine kinase (Btk) [5,6]. This
BCR signaling through PTKs has been shown to be essential for
the survival of a number of murine and human B-cell lymphoma
cell lines [7]. Importantly, LMP2A protein harbors an ITAM in its
amino-terminal cytoplasmic domain. In EBV-transformed LCLs,
the amino-terminal domain of LMP2A is constitutively phosphor-
ylated on tyrosine residues and is associated with PTKs, such as
Lyn and Syk [8]. LMP2A can block BCR signal transduction and
prevent the activation of lytic replication of EBV in LCLs thus
maintaining virus latency [9–11]. Moreover, LMP2A can act as a
BCR mimic, since human B cells, which do not express functional
BCR, are rescued from apoptosis when are infected with wild type
EBV, but not with EBV lacking LMP2A [12]. In accordance with
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this, studies in transgenic mice that express LMP2A in B cells have
shown that LMP2A expression can promote survival in BCR-
negative cells [13,14].
Apart from PTKs, the Raf/MEK/ERK pathway has been
implicated in transformed B cell survival although the role of this
pathway in the survival of EBV-transformed human B cells is
unclear. ERKs can be activated by either LMP1 or LMP2A
among the latent EBV antigens [15,16]. Interestingly, LMP1-
mediated Erk activation is essential for Rat1 transformation by
LMP1 [15]. Furthermore, sustained Erk activation by LMP2A can
provide an essential survival function in developing B cells [17].
These findings support a prosurvival role of the ERK pathway in
B lymphocyte transformation by EBV.
Given their crucial role in the development of B-cell malignan-
cies, protein kinases are potential targets for anticancer therapies
[18,19]. Protein kinase inhibitors (PKIs) are useful tools for this
strategy and have already been used as drugs against several types
of cancer (reviewed in [20]). In this study, a library of 254 PKIs
was screened in order to identify inhibitors that show specific
activity against EBV-infected B cells. Importantly, two tyrosine
kinase inhibitors, as well as two MEK inhibitors, out of the 254
tested, were found to impair more potently the viability of EBV-
infected cells compared to non-infected B cells. These results
indicate that the impact of inhibition of specific protein kinases in
cell viability differs among B lymphocytes in a manner that may
depend on latent EBV infection. Consequently, the use of specific
kinase inhibitors may prove to be beneficial for the treatment of
EBV-related lymphomas.
Materials and Methods
Ethics Statement
The use of human samples was approved by the responsible
Institutional Review Board (George Papanicolaou Hospital Board
of Directors, reference number: ADA B43346906B-S6E). The
participants provided their written informed consent to participate
in this study.
Inhibitors
The 254 PKIs that were tested in this study constitute part of
the Chemical Validation Library (CVL), which is the core library
of the Nested Chemical Library of Vichem and consists of
launched kinase inhibitor drugs and compounds in clinical trials
and in preclinical development (http://www.vichem.hu/
nested_chemical_library.html) [21]. Four of these 254 PKIs were
further studied; PP2 is an inhibitor of Src family tyrosine kinases
with higher potency for Lck and Fyn. Compound 5 also inhibits
Src family kinases with Lck being the most sensitive. CI-1040 and
PD 198306 are MEK inhibitors. PP2, CI-1040 and PD 198306
have already been used in pharmacological studies [22–24].
Inhibitors were synthesized according to literature procedures:
PP2 [25], compound 5 [26], CI-1040 and PD 198306 [27]. A-
770041 (Axon Medchem) is a selective inhibitor of Lck, while
U0126 (Gibco) is a selective inhibitor of MEK1 and MEK2. All
inhibitors were dissolved in DMSO.
Cell lines and tissue culture reagents
LCL-WT [28] and LCL-FLAG-LMP1 [29] are EBV trans-
formed lymphoblastoid cell lines. BL41-B95-8 [30] is an EBV-
positive (EBV+) Burkitt’s lymphoma cell line, while BL41 [31] and
DG75 [32] are EBV-negative (EBV-) Burkitt’s lymphoma cell
lines. Human peripheral blood mononuclear cells (PBMCs) from
healthy donors were isolated using Histopaque-1077 (Sigma-
Aldrich), according to the instructions of the manufacturer. B cell
lines and PBMCs were cultured in RPMI1460 (Invitrogen)
supplemented with 10% fetal bovine serum, L-glutamine
(2 mM), penicillin (100 units/mL) and streptomycin (0.1 mg/mL).
Viability assay
B cells or PBMCs were seeded in 12 well plates (day 0).
Different concentrations of each inhibitor were added in the
cultures at days 0 and 2. Cell viability was measured at day 4
either by trypan blue exclusion or using MTT assay and expressed
as percent survival, which was calculated by comparing the
viability of treated vs DMSO treated cells and assigning the latter
the value of 100%. IC50s were calculated in GraphPad Prism
software using a four parameters fitting. Top and Bottom
constrains were set to 100 and 0. Values with R2.0.8 regression
are displayed in Table 1.
Apoptosis assay
B cells were seeded in 12 well plates at a concentration of
105 cells/ml and each inhibitor was added in two doses, at days 0
and 2 after seeding. One day after the last dose, cells were
harvested, stained with Annexin V-FITC (eBioscience) and
propidium iodide (PI, eBioscience), according to the instructions
of the manufacturer, and the percentage of the early apoptotic
cells was measured using flow cytometry.
Western blot analysis
105 B cells/ml were seeded in 6 well plates and incubated with
inhibitors for up to 48 hours. Cells (at least 56105) were harvested
at specific time points and whole extracts were isolated by boiling
the cells in sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) loading buffer for 10 minutes. Cell isolates were
analyzed by SDS-PAGE, followed by electrophoretic transfer and
immunoblotting. Antibodies against phospho-ERK (E-4; Santa
Cruz Biotechnology), ERK 2 (C-14; Santa Cruz Biotechnology),
b-actin (C4; Santa Cruz Biotechnology) and tyrosine kinase
substrates (4G10 anti-phosphotyrosine) were used for Western blot
analysis.
RNA interference and electroporation assay
The expression of Lck and MEK1 genes was downregulated
using short hairpin RNA (shRNA) expression vectors. These
vectors were constructed by cloning appropriate oligonucleotides
into the pHEBo-SUPER plasmid [33] between the unique BglII
and HindIII sites of its polylinker. The oligonucleotide sequences
that were used were the following: LCK(A)(for); 59- GATCCC-
CACGGAATTATATTCATCGTGACTTCAAGAGAGTCAC-
GATGAATATAATTCCGCTTTTTA- 39 and LCK(A)(rev); 59-
AGCTTAAAAAGCGGAATTATATTCATCGTGACTCTCT-
TGAAGTCACGATGAATATAATTCCGTGGG-39 for the
construction of the pHEBo-Lck(A) shRNA-expression vector
against LCK, LCK(B)(for); 59- GATCCCCCCCTGGACATGG-
CAGCCCAAATTTCAAGAGAATTTGGGCTGCCATGTCC-
AGGATTTTTA- 39 and LCK(B)(rev); 59- AGCTTAAAAAT-
CCTGGACATGGCAGCCCAAATTCTCTTGAAATTTGGG-
CTGCCATGTCCAGGGGGG-39 for the construction of the
pHEBo-Lck(B) shRNA-expression vector against LCK, ME-
K1A(for); 59-GATCCCCCGGTCCTACATGTCGCCAGAAA-
TTCAAGAGATTTCTGGCGACATGTAGGACCTTTTTTA-
39 and MEK1A(rev); 59- AGCTTAAAAAAGGTCCTA-
CATGTCGCCAGAAATCTCTTGAATTTCTGGCGACATG-
TAGGACCGGGG-39 for the construction of the pHEBo-
MEK1(A) shRNA-expression vector against MEK1, and
MEK1B(for); 59- GATCCCCCGGTCATGGCCAGAAAGC-
Inhibitors of EBV-Infected B Lymphocytes
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TAATTTCAAGAGAATTAGCTTTCTGGCCATGACCATT-
TTTA-39 and MEK1B(rev); 59- AGCTTAAAAATGGT-
CATGGCCAGAAAGCTAATTCTCTTGAAATTAGCTTTC-
TGGCCATGACCGGGG-39 for the construction of the
pHEBo-MEK1(B) shRNA-expression vector against MEK1.
36106 cells of LCL-WT or LCL-FLAG-LMP1 were suspended
in 250 mL Opti-MEM I Reduced Serum Medium (Gibco). Cells
were electroporated with 5 mg pMAX-GFP and 10 mg pHEBo-
SUPER at 140 V and 1000 mF in a 0.2 cm cuvette (Bio-Rad)
and then transferred in 1.5 ml culture medium. shRNAs against
GAPDH and luciferase gene were used as negative and positive
control respectively. Two days after electroporation the
percentage of transfected cells was determined via the detection
of green fluorescent protein (GFP) using flow cytometry, and
26105 of the cells were placed in 1.5 ml medium supplemented
with hygromycin at the concentration of 200 mg/ml. Cell
viability was measured using the MTT assay.
Statistical analysis
Data are presented as means 6 standard error of the mean
(SEM). The statistical evaluation was performed using Student’s t-
test. All statistical analyses were performed with Statistica 5.0. p
values of #.05 were considered significant.
Results
Tyrosine kinase inhibitors and ERK inhibitors exert a
selective negative effect on the viability of EBV-infected B
cells
In order to find kinase inhibitors that affect selectively the
viability of cancer B cell lines that are infected with Epstein-Barr
virus (EBV), a library of 254 low molecular weight kinase
inhibitors (part of Chemical Validation Library of Vichem), was
screened using cells that are either infected or non-infected by
EBV. More specifically, LCL-WT and DG75 were treated with
1 mM of each inhibitor for 4 days and then the cell viability was
evaluated by trypan blue exclusion (Figure S1). Compounds that
inhibited the viability of LCL-WT by at least 50% but did not
reduce the viability of DG75 cells by more than 50% were tested
further for their effect against an additional EBV-transformed B
cell line (LCL-FLAG-LMP1) and normal peripheral blood
mononuclear cells (PBMCs). Four compounds were found to
compromise the viability of EBV-positive cells preferentially
(Figure S1). Two of these compounds are Src family tyrosine
kinase inhibitors (PP2 and compound 5), while the other two
compounds inhibit primarily the ERK pathway through the
inhibition of MEK kinase (CI-1040 and PD 198306) (Figure 1).
In order to analyze further the action of these four inhibitors,
their dose-dependent effect on the viability of LCL-WT, LCL-
FLAG-LMP1, DG75 and PBMCs was determined. Of note, a
greater reduction in the viability of EBV+ cell lines compared to
EBV- cell lines and PBMCs was observed in all cases (Figure 2A–
D). There was at least one concentration of each inhibitor that
caused a statistically significant difference in cell viability between
EBV+ and EBV- cells. The IC50 values of PP2, Cl-1040 and PD
198306 are presented in Table 1. In the case of compound 5
approximate IC50 values are shown due to the slope of the curves
(r2,0.8).
In order to evaluate further the selectivity of the inhibitors
towards the viability of EBV+ cells, the compounds were tested
against additional cell lines. BL41 is an EBV-negative Burkitt’s
lymphoma cell line, while BL41-B95-8 has been derived by the
infection of BL41 with the B95-8 strain of EBV. Treatment of
these cell lines with the kinase inhibitors reduced the viability of
BL41-B95-8 cells to a greater extent compared to their parental
EBV- (BL41) cells (Figure 2E–H). The differential effect of the
inhibitors towards the two cells lines is also evident by the
corresponding IC50 values (Table 1). A similar pattern of results
was obtained by evaluating cell viability using the MTT assay
(data not shown).
The reduction in EBV-infected B cell viability by kinase
inhibitors correlates with apoptosis initiation
The basis for B cell viability reduction was investigated in order
to understand the mechanism of action of the kinase inhibitors.
For this purpose, each cell line that was used in the viability assay
(Figure 2) was incubated with each one of the kinase inhibitors for
72 h and the cells were subsequently analyzed for evidence of
apoptosis using Annexin V and PI staining. Notably, all inhibitors
caused a statistically significant increase in the percentage of early
apoptotic cells, as assessed by Annexin V - PI staining, in all the
EBV-infected cell lines (LCL-WT, LCL-FLAG-LMP1 and BL41-
B95-8) without affecting significantly the apoptotic profile of the
EBV- cell lines (DG75 and BL41) (Figure 3). More specifically,
treatment with the tyrosine kinase inhibitor PP2 or compound 5
induced an increase in the percentage of early apoptotic cells in
LCLs from up to 8% to at least 20% and 15% respectively
(Figures 3A and 3B). Similarly, the CI-1040 and PD 198306
inhibitors caused an increase in the percentage of early apoptotic
cells in LCLs from up to 11% to at least 20% and 25% respectively
(Figures 3A and 3B). Likewise, there was an increase in the percent
of early apoptotic BL41-B95-8 cells as a result of treatment with
PP2 (from 4.5% to 13%), compound 5 (from 5% to 9%), CI-1040
(from 5% to 15%) or the PD 198306 (from 5% to 15%) inhibitor
(Figure 3D). On the contrary, the extent of apoptosis in the EBV-
Table 1. The IC50 values of the kinase inhibitors towards B lymphoma cell lines and PBMCs are shown.
IC50 values (mM)
PP2 Compound 5 CI-1040 PD 198306
LCL-WT 0.75 ,0.05 1.00 1.89
LCL-FLAG-LMP1 1.12 ,0.05 0.41 0.96
DG75 5.81 .2 4.10 3.48
PBMCs 11.04 .8 7.92 13.72
BL41-B95-8 2.45 ,0.2 1.77 0.61
BL41 7.40 .4 4.00 2.87
doi:10.1371/journal.pone.0095688.t001
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cells DG75 (Figure 3C) and BL41 (Figure 3E) was not affected
significantly after their incubation with each of the inhibitors
under the conditions specified above, with the exception of
compound 5 which caused a statistically significant increase in the
apoptosis of BL41 cells. These findings indicate that the reduction
in cell viability by the kinase inhibitors that were used was
mediated at least in part, by induction of apoptosis. Clearly, other
processes of cell death could contribute to the reduction in cell line
viability by the PKIs used.
Targets of protein kinase inhibitors that negatively affect
the viability of EBV-infected B cells
PP2 and compound 5 are small molecule inhibitors of Src
family tyrosine kinases, whereas CI-1040 and PD 198306 inhibit
primarily the activation of MEK/ERK pathway. To analyze the
molecular mechanisms that may be responsible for the selectivity
of kinase inhibitors towards EBV-infected B cells, the levels of
proteins with phosphorylated tyrosine residues and phosphorylat-
ed ERKs were examined in the EBV+ LCL-WT and the EBV-
DG75 cells that were treated with each inhibitor for up to
48 hours. Cell extracts were isolated every 12 hours and the levels
of phospho-tyrosine as well as phospho-ERK were determined by
immunoblotting. Both PP2 and compound 5 inhibited tyrosine
phosphorylation of several proteins in the EBV+ LCL-WT
(Figure 4A and 4B) as well as in the EBV- DG75 cells (Figure 4E
and 4F) during the treatment period. In addition, we assessed the
levels of phospho-tyrosine in cell extracts, derived from Burkitt’s
lymphoma cell lines, after treatment with PP2 or compound 5 for
48 hours. Indeed, both the BL41-B95-8 (EBV+) (Figure 4I and 4J)
and the BL41 (EBV-) cell extracts (Figure 4M and 4N) exhibited
reduced tyrosine phosphorylation after treatment compared with
the untreated cells. It should be noted that in addition to similar-
size phosphotyrosine substrates, EBV+ cell extracts contained also
tyrosine-phosphorylated proteins not seen in the EBV- cell
extracts. In the case of the CI-1040 and PD 198306 compounds,
extensive and comparable reduction in the levels of phosphory-
lated ERK1-2 was observed in both LCL-WT (Figures 4C and
4D) and DG75 cells (Figures 4G and 4H) at each time point tested.
Similar results were obtained in the BL41-B95-8 (Figures 4K and
4L) and BL41 cell lines (Figures 4O and 4P). These data suggest
that inhibition of tyrosine phosphorylation of common and/or
distinct proteins by PP2 and compound 5 or ERK1-2 by CI-1040
and PD 198306, may contribute to the higher viability reduction
of EBV-infected B cells compared to the non-infected ones.
Since a common target of PP2 and compound 5 is Lck, we
investigated whether another Lck inhibitor could mimic their
effect on B lymphoma cell lines. A-770041, a known selective
inhibitor of Lck (Figure 5A), was used in order to test the influence
of Lck inhibition on the viability of EBV+ and EBV- lymphocytes.
Figure 1. The structure of kinase inhibitors used in this study. PP2 (A) and compound 5 (B) are Src-family tyrosine kinases inhibitors, while CI-
1040 (C) and PD 198306 (D) are MEK inhibitors.
doi:10.1371/journal.pone.0095688.g001
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Figure 2. The effect of kinase inhibitors on B cell and PBMC viability. The viability curves of B cells and PBMCs after four days of incubation
with different concentrations of each inhibitor are depicted. Treatment of cells with DMSO served as control. (A–D): Percent survival of LCL-WT (open
circles), LCL-flag-LMP1 (solid rectangles), DG75 (solid triangles) and PBMCs (asterisks) treated with inhibitor PP2 (A), compound 5 (B), CI-1040 (C) or PD
198306 (D). (E–H): BL41-B95-8 (open circles) and BL41 cell line (solid rectangles) percent survival after treatment with inhibitor PP2 (E), compound 5
(F), CI-1040 (G) and PD 198306(H). The results are the means 6 SEM from three independent experiments. Statistical analysis was performed using
Student’s t test. Statistically significant differences (p,0.05) in viability between each LCL and DG75 as well as PBMCs (panels A to D), or between
BL41-B95-8 and BL41 cell lines (panels E to H) are shown by *.
doi:10.1371/journal.pone.0095688.g002
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Treatment of LCL-WT, LCL-FLAG-LMP1 and DG75 cell lines
with 0.5 mM of A-770041 inhibitor for 4 days caused a higher
reduction in the viability of the two LCLs in relation to DG75
(Figure 5B). Similarly, treatment of BL41-B95-8 or BL41 with
1.5 mM of A-770041 caused a more prominent reduction in the
viability of BL41-B95-8 compared to BL41 cells (Figure 5C).
These experiments suggest that inhibition of Lck may be the basis,
at least in part, for the selective negative effect of PP2 and
compound 5 on the viability of EBV-positive B cells.
In order to investigate further the role of MEK in the viability of
EBV+ B cells the effect of U0126, a selective MEK inhibitor
(Figure 5D) was evaluated. LCL-WT, LCL-FLAG-LMP1 and
DG75 cell lines were incubated with 8 mM of U0126 for 4 days.
This treatment resulted in a negative effect on the viability of the
cells, which was more potent for LCLs than DG75 cells
(Figure 5E). This result underscores the greater dependence of
EBV-infected B cells on the activity of MEK in comparison to
non-infected B cells.
Figure 3. Apoptosis evaluation in B cell lines treated with kinase inhibitors. Cells were treated with PP2 (8 mM), compound 5 (0.05 mM for
LCL-WT, LCL-flag-LMP1 and DG75 or 1 mM for BL41-B95-8 and BL41), CI-1040 (4 mM) or PD 198306 (4 mM) for 72 hours and the apoptotic index was
assessed by Annexin V - PI staining. The percentage of early apoptotic (AnnexinV+PI-) LCL-WT (A), LCL-flag-LMP1 (B), DG75 (C), BL41-B95-8 (D) or BL41
(E) cells treated with the indicated kinase inhibitor (black column) or left untreated (white column) is shown. Results are the means 6 SEM from at
least three independent experiments. Statistical analysis was performed using Student’s t test. Statistically significant differences (p,0.05) between
treated and untreated cells are shown by *.
doi:10.1371/journal.pone.0095688.g003
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The role of Lck and MEK1 in the viability of LCLs was studied
further by using shRNAs that silence these two genes. Vectors
expressing two shRNAs that target Lck and two shRNAs that
target MEK1 were electroporated in either LCL-WT or LCL-
FLAG-LMP1 cells. After selection with hygromycin, LCL-WT
cells that were transfected with these plasmids exhibited at least
71% reduction of their viability compared with cells that were
transfected with shRNA against an irrelevant gene (luciferase).
Similar results were observed in LCL-FLAG-LMP1 cells, as the
reduction of cells’ viability was at least 68% (Figure 6).
Taken together these results indicate that the inhibition of Lck
and MEK1 may account, at least partly, for the greater sensitivity
of EBV+ versus EBV- B cells to the inhibitors that were identified
by this study.
Discussion
Protein kinases play a vital role in the survival, development and
proliferation of B cells. Hence, protein kinase inhibitors (PKI) have
been used for treatment in patients with neoplastic and chronic
inflammatory diseases. Since there are several agents, such as the
Hsp90 inhibitor 17-DMAG [34] and simvastatin [35], that have
been found to affect selectively the viability of EBV-infected cells,
we examined whether there are PKIs with similar function.
Indeed, two tyrosine kinase inhibitors, PP2 and compound 5, and
Figure 4. Effect of kinase inhibitors on tyrosine phosphorylation or ERK phosphorylation in B cell lines. LCL-WT and DG75 cell lines
were treated with PP2 (8 mM), compound 5 (0.05 mM), CI-1040 (4 mM) or PD 198306 (4 mM), while BL41-B95-8 and BL41 were treated with PP2 (2 mM),
compound 5 (0.5 mM), CI-1040 (2 mM) or PD 198306 (2 mM) for up to 48 hours. Treatment of cells with DMSO served as control. Whole cell lysates
were prepared at specific time points and protein tyrosine phosphorylation or ERK-1 and -2 phosphorylation was evaluated using immunoblotting.
Whole cell extracts obtained from LCL-WT (A–D), DG75 (E–H), BL41-B95-8 (I–L) or BL41 (M–P) after treatment with the compounds PP2 and
compound 5, or CI-1040 and PD 198306 were immunoblotted for phosphotyrosine or phospho-ERK as indicated. Results are representative of two
independent experiments.
doi:10.1371/journal.pone.0095688.g004
Figure 5. Effect of A-770041 and U0126 on B lymphoma cell viability. (A) Structure of Lck inhibitor A-770041. (B) Percent of viable cells of
LCL-WT, LCL-FLAG-LMP1 and DG75 after treatment with 0.5 mM of A-770041 for 4 days. The results are the means 6 SEM from three independent
experiments. Statistically significant (p,0.05) differences between the viability of each LCL cell line and DG75 are shown by an asterisk. (C) Percent of
viable cells of BL41-B95-8 and BL41 after treatment with 1.5 mM of A-770041 for 4 days. The results are the means 6 SEM from three independent
experiments. Statistically significant (p,0.05) differences in viability between these two cell lines is denoted by an asterisk. (D) Structure of MEK
inhibitor U0126. (E) Percent of viable cells of LCL-WT, LCL-FLAG-LMP1 and DG75 after treatment with 8 mM of U0126 for 4 days. The results are the
means 6 SEM from three independent experiments. Statistically significant (p,0.05) differences between the viability of each LCL cell line and DG75
are denoted by an asterisk.
doi:10.1371/journal.pone.0095688.g005
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two MEK inhibitors, CI-1040 and PD 198306, showed a selective
negative effect towards EBV+ cells.
Treatment with PP2 or compound 5 caused a significant
reduction in the phosphorylation level of specific substrates of all
tested cell lines, as it was found by immunoblotting (Figure 4). This
analysis revealed that a major target of PP2 and compound 5 was
a protein with molecular weight of approximately 55 kDa.
Considering Src family kinases that participate in B cell viability,
one possible candidate for the 55 kDa molecule, could be the
kinase Lck. Lck is predominantly expressed in T cells and is
undetectable in peripheral blood B cells from healthy donors.
However, it is expressed in normal B cells following transformation
by EBV [36], in chronic lymphocytic leukemia (B-CLL) [37], in
LCLs and in BL cell lines [38]. Interestingly, Lck can phosphor-
ylate the cytoplasmic tail of both Iga and Igb in vitro [39]. Since
PP2 and compound 5 were the only two inhibitors of Chemical
Validation Library (CVL) out of 254 tested that inhibit Lck, we
tested the possibility that Lck is a critical mediator of the selective
effect of these two inhibitors towards EBV+ B cells. A-770041 is a
selective inhibitor of Lck that has different molecular structure
from PP2 and compound 5 [40]. Similarly to PP2 and compound
5, A-770041 caused a higher reduction in the viability of EBV+
cells in comparison to EBV- cells (Figure 5B and 5C). Moreover,
RNA interference experiments revealed that Lck kinase is essential
for the viability of LCLs, since downregulation of Lck expression
had a potent negative effect on their viability (Figure 6A). In
summary, these data indicate that the selective negative effect of
PP2 and compound 5 on EBV+ positive B cells may be mediated,
at least in part, by Lck inhibition.
CI-1040 and PD 198306 are the only two inhibitors of CVL
compounds that inhibit ERK1/2 phosphorylation. Deregulation
of the MEK/ERK pathway has been associated with sensitivity
and resistance to leukemia therapy highlighting the importance of
this pathway for controlling hemopoietic malignancies [41].
U0126 is a selective MEK inhibitor, structurally dissimilar
compared to CI-1040 and PD 198306 [42]. Treatment with
U0126 led to increased cell death of LCLs compared to DG75
(Figure 5E). However, the pair of BL41 and BL41-B95-8 cell lines
didn’t exhibit similar results. BL41-B95-8 cells weren’t more
sensitive than BL41 to U0126 (data not shown). Recently it was
found that U0126 and other MEK inhibitors have off-target
effects, independent of their ability to inhibit MEK1/2 [43]. This
finding could explain the similar influence of U0126 on the
viability of BL41 and BL41-B95-8 cell lines.
Figure 6. Effect of LCK and MEK1 downregulation on LCL viability. The viability of EBV-transformed LCL was assessed following the
expression of shRNAs against Lck (A) or MEK1 (C) in LCL-WT (black bars) and LCL-FLAG-LMP1 cells (white bars). Cells transfected with shRNA-
expression vectors against luciferase gene were used as reference control. The results are the means 6 SEM from three independent experiments.
Differences in viability between transfected cells with pHEBo-Luc and pHEBo-LCK or pHEBo-MEK1 vectors are statistically significant (p,0.05). (B and
D) Downregulation of Lck (B) or MEK1 (D) mRNA expression by pHEBo vectors. 293FT cells were transfected with pHEBo-Lck (2 mg) or pHEBo-MEK1
(2 mg) or pHEBo-Luc (2 mg). RNA extracts were isolated two days after transfection and the levels of the expression of Lck or MEK1 gene were
estimated by RT-PCR. The results from a representative experiment out of two independent experiments are shown.
doi:10.1371/journal.pone.0095688.g006
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Although our experiments indicate that Lck or MEK kinase
inhibition contributes to the selective negative effect of the four
inhibitors on EBV+ B cells, it should be pointed out that additional
effects of the four inhibitors on unknown kinases may shape as well
their overall effect towards EBV+ B cells. In addition, it should be
stressed that although our data clearly indicate a differential
sensitivity between EBV+ and EBV- B cells to the four kinase
inhibitors identified by our screen, this notion cannot be fully
generalized since polymorphisms, mutations and other types of
chromatin modifications may alter the response of individual B
lymphoma cells to the inhibitors used. Nevertheless, our results
have identified four kinase inhibitors that could provide the
structural basis for the development of small molecule therapeutics
with selective activity against EBV-associated B cell malignancies.
Supporting Information
Figure S1 Initial screening of the Chemical Validation
Library. LCL- WT and DG75 cells were treated with each one
of 254 kinase inhibitors (1 mM) of the Chemical Validation Library
for 4 days. The results are the means from three independent
experiments. Compounds that inhibited the viability of LCL-WT
by at least 50% but did not reduce the viability of DG75 cells by
more than 50% were tested further for their effect against an
additional EBV-transformed B cell line (LCL-FLAG-LMP1) and
PBMCs. The four inhibitors (PP2, compound 5, CI-1040 and PD
198306) that were found to compromise the viability of EBV-
positive cells preferentially and analyzed in the present study are
indicated by arrows. The rest of the inhibitors of the upper left
quadrant were not analyzed further because they did not exhibit
similar results, when tested against LCL-FLAG-LMP1 and
PBMCs.
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